Чучалин А.Г. Бронхиальная астма. М.: Медицина; 1985. 160 с. Режим доступа: https://studfile.net/preview/1564756/.https://studfile.net/preview/1564756/
Чучалин А.Г. Бронхиальная астма. М.: Медицина; 1985. 160 с. Режим доступа: https://studfile.net/preview/1564756/.https://studfile.net/preview/1564756/
Dahlén S.E. Asthma phenotyping: noninvasive biomarkers suitable for bedside science are the next step to implement precision medicine. J Intern Med. 2016;279(2):205–207. https://doi.org/10.1111/joim.12466..
DOI: 10.1111/joim.12466
Ishizaka T., Ishizaka K., Johansson S.G., Bennich H. Histamine release from human leukocytes by anti-gamma E antibodies. J Immunol. 1969;102(4): 884–892. Available at: https://www.jimmunol.org/content/102/4/884/tabarticle-info.https://www.jimmunol.org/content/102/4/884/tabarticle-info
Ishizaka T., Ishizaka K., Johansson S.G., Bennich H. Histamine release from human leukocytes by anti-gamma E antibodies. J Immunol. 1969;102(4): 884–892. Available at: https://www.jimmunol.org/content/102/4/884/tabarticle-info.https://www.jimmunol.org/content/102/4/884/tab-article-info
Ishizaka K., Ishizaka T. Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol. 1967;99(6):1187–1198. Available at: https://www.jimmunol.org/content/99/6/1187.long.https://www.jimmunol.org/content/99/6/1187.long
Ishizaka K., Ishizaka T. Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol. 1967;99(6):1187–1198. Available at: https://www.jimmunol.org/content/99/6/1187.long.https://www.jimmunol.org/content/99/6/1187.long
Johansson S.G. Discovery and development of IgE assays. Clin Exp Allergy. 1997;27(1 Suppl.):60–63. https://doi.org/10.1111/j.1365-2222.1997.tb01828.x..
DOI: 10.1111/j.1365-2222.1997.tb01828.x
Johansson S.G., Hourihane J.O., Bousquet J., Bruijnzeel-Koomen C., Dreborg S., Haahtela T. et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56(9):813–824. https://doi.org/10.1034/j.1398-9995.2001.t01-1-00001.x..
DOI: 10.1034/j.1398-9995.2001.t01-1-00001.x
Johansson S.G. Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet. 1967;2(7523):951–953. https://doi.org/10.1016/s0140-6736(67)90792-1..
DOI: 10.1016/s0140-6736(67)90792-1
Stanworth D.R. The discovery of IgE. Allergy. 1993;48(2):67–71. https://doi.org/10.1111/j.1398-9995.1993.tb00687.x..
DOI: 10.1111/j.1398-9995.1993.tb00687.x
Johansson S.G. The History of IgE: From discovery to 2010. Curr Allergy Asthma Rep. 2011;11(2):173–177. https://doi.org/10.1007/s11882-010-0174-3..
DOI: 10.1007/s11882-010-0174-3
Мачарадзе Д.Ш. Современные клинические аспекты оценки уровней общего и специфических IgE. Педиатрия. Журнал имени Г.Н. Сперанского. 2017;96(2):121–127. Режим доступа: https://pediatriajournal.ru/archive?show=357§ion=4881.https://pediatriajournal.ru/archive?show=357§ion=4881
Мачарадзе Д.Ш. Современные клинические аспекты оценки уровней общего и специфических IgE. Педиатрия. Журнал имени Г.Н. Сперанского. 2017;96(2):121–127. Режим доступа: https://pediatriajournal.ru/archive?show=357§ion=4881.https://pediatriajournal.ru/archive?show=357§ion=4881
Lloyd C.M., Robinson D.S. Allergen-induced airway remodelling. Eur Respir J. 2007;29(5):1020–1032. https://doi.org/10.1183/09031936.00150305..
DOI: 10.1183/09031936.00150305
Romagnoli M., Caramori G., Braccioni F., Ravenna F., Barreiro E., Siafakas N.M. et al. Near-fatal asthma phenotype in the ENFUMOSA Cohort. Clin Exp Allergy. 2007;37(4):552–557. https://doi.org/10.1111/j.1365-2222.2007.02683.x..
DOI: 10.1111/j.1365-2222.2007.02683.x
Osborne M., Deffebach M. The epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study. Ann Allergy Asthma Immunol. 2004;92(1):3. https://doi.org/10.1016/S1081-1206(10)61702-4..
DOI: 10.1016/S1081-1206(10)61702-4
Pearce N., Beasley R., Crane J., Burgess C., Jackson R. End of the New Zealand asthma mortality epidemic. Lancet. 1995;345(8941):41–44. https://doi.org/10.1016/s0140-6736(95)91159-6..
DOI: 10.1016/s0140-6736(95)91159-6
Kinoshita H., Kubota A., Kasuda S., Nishiguchi M., Ouchi H., Minami T. et al. An autopsy case of asthmatic death – usefulness of biochemical examination. Vojnosanit Pregl. 2008;65(5):404–406. https://doi.org/10.2298/vsp0805404k..
DOI: 10.2298/vsp0805404k
Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998;351(9111): 1225–1232. https://doi.org/10.1016/S0140-6736(97)07302-9..
DOI: 10.1016/S0140-6736(97)07302-9
Asher M.I., Stewart A.W., Mallol J., Montefort S., Lai C.K., Aït-Khaled N., Odhiambo J. Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One. Respir Res. 2010;11(1):8. https://doi.org/10.1186/1465-9921-11-8..
DOI: 10.1186/1465-9921-11-8
Shaaban R., Zureik M., Soussan D., Neukirch C., Heinrich J., Sunyer J. et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet. 2008;372(9643):1049–1057. https://doi.org/10.1016/S0140-6736(08)61446-4..
DOI: 10.1016/S0140-6736(08)61446-4
Fokkens W., Lund V., Mullol J. European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl. 2007;20:1–136. Available at: https://pubmed.ncbi.nlm.nih.gov/17844873/.https://pubmed.ncbi.nlm.nih.gov/17844873/
Fokkens W., Lund V., Mullol J. European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl. 2007;20:1–136. Available at: https://pubmed.ncbi.nlm.nih.gov/17844873/.https://pubmed.ncbi.nlm.nih.gov/17844873/
Brożek J.L., Bousquet J., Agache I., Agarwal A., Bachert C., Bosnic-Anticevich S. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958. https://doi.org/10.1016/j.jaci.2017.03.050..
DOI: 10.1016/j.jaci.2017.03.050
Kwah J.H., Peters A.T. Nasal polyps and rhinosinusitis. Allergy Asthma Proc. 2019;40(6):380–384. https://doi.org/10.2500/aap.2019.40.4252..
DOI: 10.2500/aap.2019.40.4252
Agache I., Beltran J., Akdis C., Akdis M., Canelo-Aybar C., Canonica G.W. et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042. https://doi.org/10.1111/all.14221..
DOI: 10.1111/all.14221
Molimard M., Mala L., Bourdeix I., Le Gros V. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med. 2014;108(4):571–576. https://doi.org/10.1016/j.rmed.2014.02.003..
DOI: 10.1016/j.rmed.2014.02.003
Козлов В.А., Савченко А.А., Кудрявцев И.В., Козлов И.Г., Кудлай Д.А., Продеус А.П., Борисов А.Г. Клиническая иммунология. Красноярск: Поликор; 2020. 386 с. https://doi.org/10.17513/np.438..
DOI: 10.17513/np.438
Gandhi N.A., Pirozzi G., Graham N.M.H. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. https://doi.org/10.1080/1744666X.2017.1298443..
DOI: 10.1080/1744666X.2017.1298443
Castro M., Zangrilli J., Wechsler M.E., Bateman E.D., Brusselle G.G., Bardin P. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. https://doi.org/10.1016/S2213-2600(15)00042-9..
DOI: 10.1016/S2213-2600(15)00042-9
Ortega H.G., Yancey S.W., Mayer B., Gunsoy N.B., Keene O.N., Bleecker E.R. et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556. https://doi.org/10.1016/S2213-2600(16)30031-5..
DOI: 10.1016/S2213-2600(16)30031-5
Bleecker E.R., FitzGerald J.M., Chanez P., Papi A., Weinstein S.F., Barker P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. https://doi.org/10.1016/S0140-6736(16)31324-1..
DOI: 10.1016/S0140-6736(16)31324-1
Иванов Р., Секарёва Г., Кравцова О., Кудлай Д., Лукьянов С., Тихонова И. и др. Правила проведения исследований биоаналоговых лекарственных средств (биоаналогов). Фармакокинетика и фармакодинамика. 2014;(1):21–36. Режим доступа: https://www.pharmacokinetica.ru/jour/article/view/138.https://www.pharmacokinetica.ru/jour/article/view/138
Иванов Р., Секарёва Г., Кравцова О., Кудлай Д., Лукьянов С., Тихонова И. и др. Правила проведения исследований биоаналоговых лекарственных средств (биоаналогов). Фармакокинетика и фармакодинамика. 2014;(1):21–36. Режим доступа: https://www.pharmacokinetica.ru/jour/article/view/138.https://www.pharmacokinetica.ru/jour/article/view/138
Ненашева Н.М., Аверьянов А.В., Ильина Н.И., Авдеев С.Н., Осипова Г.Л., Рубаник Т.В. и др. Сравнительное изучение клинической эффективности биоаналогичного препарата Генолар® по результатам рандомизированного клинического исследования III фазы. Пульмонология. 2020;30(6): 782–796. https://doi.org/10.18093/0869-0189-2020-30-6-782-796..
DOI: 10.18093/0869-0189-2020-30-6-782-796
Palomares Ó., Sánchez-Ramón S., Dávila I., Prieto L., Pérez de Llano L., Lleonart M. et al. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. Int J Mol Sci. 2017;18(6):1328. https://doi.org/10.3390/ijms18061328..
DOI: 10.3390/ijms18061328
Ayres J.G., Higgins B., Chilvers E.R., Ayre G., Blogg M., Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59(7):701–708. https://doi.org/10.1111/j.1398-9995.2004.00533.x..
DOI: 10.1111/j.1398-9995.2004.00533.x
Heymann P.W., Platts-Mills T.A.E., Woodfolk J.A., Borish L., Murphy D.D., Carper H.T. et al. Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE. J Allergy Clin Immunol. 2020;146(3):545–554. https://doi.org/10.1016/j.jaci.2020.01.035..
DOI: 10.1016/j.jaci.2020.01.035
Henriksen D.P., Bodtger U., Sidenius K., Maltbaek N., Pedersen L., Madsen H. et al. Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. Allergy Asthma Clin Immunol. 2020;16:49. https://doi.org/10.1186/s13223-020-00442-0..
DOI: 10.1186/s13223-020-00442-0
Pfaller B., José Yepes-Nuñez J., Agache I., Akdis C.A., Alsalamah M., Bavbek S. et al. Biologicals in atopic disease in pregnancy: An EAACI position paper. Allergy. 2021;76(1):71–89. https://doi.org/10.1111/all.14282..
DOI: 10.1111/all.14282
Djukanović R., Wilson S.J., Kraft M., Jarjour N.N., Steel M., Chung K.F. et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–593. https://doi.org/10.1164/rccm.200312-1651OC..
DOI: 10.1164/rccm.200312-1651OC
Van Rensen E.L., Evertse C.E., van Schadewijk W.A., van Wijngaarden S., Ayre G., Mauad T. et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy. 2009;64(1):72–80. https://doi.org/10.1111/j.1398-9995.2008.01881.x..
DOI: 10.1111/j.1398-9995.2008.01881.x
Noga O., Hanf G., Brachmann I., Klucken A.C., Kleine-Tebbe J., Rosseau S. et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006;117(6):1493–1499. https://doi.org/10.1016/j.jaci.2006.02.028..
DOI: 10.1016/j.jaci.2006.02.028
Simeone-Penney M.C., Severgnini M., Rozo L., Takahashi S., Cochran B.H., Simon A.R. PDGF-induced human airway smooth muscle cell proliferation requires STAT3 and the small GTPase Rac1. Am J Physiol Lung Cell Mol Physiol. 2008;294(4):L698–L704. https://doi.org/10.1152/ajplung.00529.2007..
DOI: 10.1152/ajplung.00529.2007
Rabe K.F., Calhoun W.J., Smith N., Jimenez P. Can anti-IgE therapy prevent airway remodeling in allergic asthma? Allergy. 2011;66(9):1142–1145. https://doi.org/10.1111/j.1398-9995.2011.02617.x..
DOI: 10.1111/j.1398-9995.2011.02617.x
Dal Negro R.W., Micheletto C., De Ferrari L., Folli C., Chiappori A., Canonica G.W. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol. 2012;25(2):475–484. https://doi.org/10.1177/039463201202500217..
DOI: 10.1177/039463201202500217
Riccio A.M., Mauri P., De Ferrari L., Rossi R., Di Silvestre D., Benazzi L. et al. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. Clin Transl Allergy. 2017;7:6. https://doi.org/10.1186/s13601-017-0143-1..
DOI: 10.1186/s13601-017-0143-1
Solidoro P., Patrucco F., de Blasio F., Brussino L., Bellocchia M., Dassetto D. et al. Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study. Ther Adv Respir Dis. 2019;13:1753466619841274. https://doi.org/10.1177/1753466619841274..
DOI: 10.1177/1753466619841274
Hoshino M., Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration. 2012;83(6):520–528. https://doi.org/10.1159/000334701..
DOI: 10.1159/000334701
Tajiri T., Niimi A., Matsumoto H., Ito I., Oguma T., Otsuka K. et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a timeseries observational study. Ann Allergy Asthma Immunol. 2014;113(4):470.e2–475.e2. https://doi.org/10.1016/j.anai.2014.06.004..
DOI: 10.1016/j.anai.2014.06.004
Pan S., Conaway S. Jr, Deshpande D.A. Mitochondrial regulation of airway smooth muscle functions in health and pulmonary diseases. Arch Biochem Biophys. 2019;663:109–119. https://doi.org/10.1016/j.abb.2019.01.002..
DOI: 10.1016/j.abb.2019.01.002
Roth M., Zhao F., Zhong J., Lardinois D., Tamm M. Serum IgE induced airway smooth muscle cell remodeling is independent of allergens and is prevented by omalizumab. PLoS ONE. 2015;10(9):e0136549. https://doi.org/10.1371/journal.pone.0136549..
DOI: 10.1371/journal.pone.0136549
Roth M., Tamm M. The effects of omalizumab on IgE induced cytokine synthesis by asthmatic airway smooth muscle cells. Ann Allergy Asthma Immunol. 2010;104(2):152–160. https://doi.org/10.1016/j.anai.2009.11.022..
DOI: 10.1016/j.anai.2009.11.022
Vennera M.D.C., Sabadell C., Picado C. Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma. Thorax. 2018;73(8):782–784. https://doi.org/10.1136/thoraxjnl-2017-210017..
DOI: 10.1136/thoraxjnl-2017-210017
Baena-Cagnani C.E., Teijeiro A., Canonica G.W. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. Curr Opin Allergy Clin Immunol. 2015;15(3):267–271. https://doi.org/10.1097/ACI.0000000000000161..
DOI: 10.1097/ACI.0000000000000161
Kim D.H., Park K.Y., Kim B.J., Kim M.N., Mun S.K. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38(5):496–500. https://doi.org/10.1111/j.1365-2230.2012.04438.x..
DOI: 10.1111/j.1365-2230.2012.04438.x
Naclerio R.M., Baroody F.M., Pinto J.M. Should clinicians use omalizumab for the treatment of nasal polyps? J Allergy Clin Immunol. 2013;132(1):247. https://doi.org/10.1016/j.jaci.2013.04.001..
DOI: 10.1016/j.jaci.2013.04.001
Gevaert P., Calus L., Van Zele T., Blomme K., De Ruyck N., Bauters W. et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110.e1–116.e1. https://doi.org/10.1016/j.jaci.2012.07.047..
DOI: 10.1016/j.jaci.2012.07.047